Seres Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Seres Therapeutics Inc.
- Former names
- Seres Health, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MCRB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001609809
- EIN
- 27-4326290
Board of directors
-
Claire Fraser · DirectorSince 2023
-
Dennis A. Ausiello · DirectorSince 2023
-
Eric D. Shaff · Director · CEO and PresidentSince 2023
-
Gregory Behar · DirectorSince 2023
-
Hans-Juergen Woerle · DirectorSince 2025
-
Kurt Graves · DirectorSince 2023
-
Paul Biondi · DirectorSince 2023
-
Richard N. Kender · Director · See RemarksSince 2023
-
Robert L. Rosiello · DirectorSince 2025
-
Stephen Berenson · DirectorSince 2023
-
Willard H. Dere · DirectorSince 2023
Chief executives
Eric D. Shaff
· CEO and President
Dates unknown
Director election results
Annual meeting of April 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
61.0%
-
63.1%
-
63.9%
Board connections
6 of this board's directors also sit on 10 other boards.
- via Dennis A. Ausiello
- via Claire Fraser
- via Richard N. Kender
- via Willard H. Dere
- via Richard N. Kender
- via Willard H. Dere
- via Stephen Berenson
- via Dennis A. Ausiello
- via Robert L. Rosiello
- via Claire Fraser
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $54,884
- 16 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Brady Kelly Officer (See Remarks) | Open-market sale | −64 | $4.55 | $291 |
| Aug 17, 2026 | DesRosier Thomas Officer (See Remarks) | Open-market sale | −82 | $4.55 | $373 |
| Aug 17, 2026 | Henn Matthew R Officer (See Remarks) | Open-market sale | −81 | $4.55 | $369 |
| Aug 17, 2026 | Eric D. Shaff Director | Open-market sale | −263 | $4.55 | $1,197 |
| Aug 15, 2026 | Brady Kelly Officer (See Remarks) | Option exercise | +181 | — | — |
| Aug 15, 2026 | DesRosier Thomas Officer (See Remarks) | Option exercise | +245 | — | — |
| Aug 15, 2026 | Henn Matthew R Officer (See Remarks) | Option exercise | +238 | — | — |
| Aug 15, 2026 | Eric D. Shaff Director | Option exercise | +722 | — | — |
| May 18, 2026 | Eric D. Shaff Director | Open-market sale | −259 | $7.53 | $1,950 |
| May 18, 2026 | Brady Kelly Officer (See Remarks) | Open-market sale | −59 | $7.53 | $444 |
| May 18, 2026 | DesRosier Thomas Officer (See Remarks) | Open-market sale | −79 | $7.53 | $595 |
| May 18, 2026 | Henn Matthew R Officer (See Remarks) | Open-market sale | −77 | $7.53 | $580 |
| May 15, 2026 | Eric D. Shaff Director | Option exercise | +722 | — | — |
| May 15, 2026 | Brady Kelly Officer (See Remarks) | Option exercise | +180 | — | — |
| May 15, 2026 | DesRosier Thomas Officer (See Remarks) | Option exercise | +244 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.